PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Xinyi Mu

Discovery Institute

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 12, 2026 · JOURNAL ARTICLE

Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of Brca1 in oocytes

Frontiers in Endocrinology

Preclinical animal model study raising a novel question about BRCA1 deficiency and ovarian toxicity from combination therapy; does not yet support clinical practice changes.

Hypothesis-GeneratingYujie Cao BRCA Gene Mutations in Cancer Nadeen Zerafa

Reported

Cyclophosphamide dose75 mg/kg, single intraperitoneal injection

Olaparib dose and duration50 mg/kg daily subcutaneous for 28 days

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support